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Cellular phenotype plasticity between the epithelial and mesenchymal states
has been linked to metastasis and heterogeneous responses to cancer ther-
apy, and remains a challenge for the treatment of triple-negative breast
cancer (TNBC). Here, we used isogenic human breast epithelial cell lines,
D492 and D492M, representing the epithelial and mesenchymal pheno-
types, respectively. We employed a CRISPR-Cas9 loss-of-function screen
targeting a 2240-gene ‘druggable genome’ to identify phenotype-specific
vulnerabilities. Cells with the epithelial phenotype were more vulnerable to
the loss of genes related to EGFR-RAS-MAPK signaling, while the mes-
enchymal-like cells had increased sensitivity to knockout of G2-M cell cycle
regulators. Furthermore, we discovered knockouts that sensitize to the
mTOR inhibitor everolimus and the chemotherapeutic drug fluorouracil in
a phenotype-specific manner. Specifically, loss of EGFR and fatty acid syn-
thase (FASN) increased the effectiveness of the drugs in the epithelial and
mesenchymal phenotypes, respectively. These phenotype-associated genetic
vulnerabilities were confirmed using targeted inhibitors of EGFR (gefi-
tinib), G2-M transition (STLC), and FASN (Fasnall). In conclusion, a
CRISPR-Cas9 loss-of-function screen enables the identification of pheno-
type-specific genetic vulnerabilities that can pinpoint actionable targets and
promising therapeutic combinations.
Abbreviations
5-FU, fluorouracil; BC, breast cancer; CRISPR, clustered regularly interspaced short palindromic repeats; CTG, CellTiter-Glo; EG5, kinesin 5;
EGFR, epidermal growth factor receptor; EMT, epithelial–mesenchymal transition; FASN, fatty acid synthase; mTOR, mammalian target of
rapamycin; RPPA, reverse-phase protein array; RSA, redundant siRNA analysis; sgRNA, single-guide RNA; STLC, S-trityl-L-cysteine inhibitor;
TGF-b, transforming growth factor-beta; TNBC, triple-negative breast cancer.
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1. Introduction
Despite the substantial improvements in therapy over
the last few decades, high-risk and metastatic breast
cancer (BC) continues to be a demanding clinical chal-
lenge, causing the death of over 600 000 women glob-
ally each year [1]. Triple-negative breast cancer
(TNBC; estrogen and progesterone receptors and
HER2-negative) has the worst clinical outcome and
lacks effective treatment options. The failure of BC
management is caused, in part, by the phenotypic
plasticity of the cancer cells that contributes to metas-
tasis and heterogeneous responses to therapy facilitat-
ing treatment resistance [2,3]. Phenotype plasticity,
encompassing both epithelial–mesenchymal transition
(EMT) and the reverse process, describes the cells’
ability to interconvert between phenotypic states along
the EMT spectrum [4]. The epithelial phenotype char-
acterizes polarized cells with cytokeratin-based
cytoskeleton that are interconnected through E-cad-
herin-based junctions. The transition to a mesenchy-
mal phenotype includes the loss of polarity, the shift
to a vimentin-based cytoskeleton, reduced cell–cell
adhesion associated with an E-cadherin to N-cadherin
switch, and increased motility and invasiveness [5].
EMT features, high phenotypic heterogeneity, and
plasticity are frequently observed in TNBC [3,6]. Cells
carrying a mesenchymal phenotype are considered to
be more resistant to conventional therapies [7]. In
addition, therapy-induced switching between pheno-
typic states has been linked to acquired resistance
[3,8]. Since distinct phenotypic states can show differ-
ent sensitivity to drugs, and phenotype switching can
confer tolerance to the applied treatment, a combina-
tion of phenotype-specific drugs could be beneficial. In
line with this, computational simulations predict that
combination therapy regimens that frequently alter-
nate between epithelial- and mesenchymal-specific
treatments could have enhanced benefit [9]. It is there-
fore important to identify genes or pathways that rep-
resent phenotype-associated vulnerabilities and could
be exploited as actionable targets in a phenotype-
specific manner.
Here, we set out to identify phenotype-specific vul-
nerability nodes in the epithelial and mesenchymal
phenotype cells. We made use of an isogenic pair of
human breast epithelial cell lines, D492 and D492M
[10–12]. Similar to other known models of EMT that
consist of isogenic pairs of breast cell lines, such as
HMLE and PMC42 [13,14], D492 and D492M cells
display distinct, epithelial and mesenchymal pheno-
types, respectively. Using the D492-D492M cell
system, we performed a clustered regularly inter-
spaced short palindrome repeat (CRISPR) loss-of-
function screen employing a 2240-gene ‘druggable
genome’ library covering targetable proteins or pro-
teins in targetable pathways. We sought to discover
genes and pathways that are selectively critical alone
for either of the phenotypes, or selectively critical
when lost in combination with drug treatment. For
the latter, we combined a CRISPR-Cas9 loss-of-func-
tion screen with compounds that are clinically used
for the treatment of BC. We selected fluorouracil (5-
FU), a conventional cytotoxic chemotherapeutic
agent, and everolimus, a targeted inhibitor of the
mammalian target of rapamycin (mTOR) serine/thre-
onine kinase, as two mechanistically distinct types of
therapies.
5-FU inhibits thymidylate synthase, leading to the
disruption of DNA and RNA synthesis and repair,
which results in cell death [15]. 5-FU and its prodrug
capecitabine are recommended for patients with locally
advanced or metastatic BC and as a salvage therapy in
nonresponding BC undergoing chemotherapy before
surgery [16,17]. A relatively high tolerance for 5-FU-
based drugs makes them suitable for combination
treatments. Multiple clinical trials testing capecitabine
together with other forms of chemotherapy have
demonstrated a moderate increase in disease-free sur-
vival in BC [18,19].
Everolimus targets mTOR, one of the major nodes
of the oncogenic PI3K-AKT-mTOR signaling path-
way [20], which is often activated in BC, also in
TNBC [21]. It has been reported that the activation
of the PI3K-AKT-mTOR signaling is associated with
EMT in both normal immortalized cells and in a
range of cancer cell lines [22–24]. Everolimus is
approved for the treatment of estrogen receptor-posi-
tive BC in combination with hormone therapy, where
it significantly improves progression-free survival [25].
In TNBC, clinical trials of combination treatments
with everolimus have not revealed clear benefit ([26]
and reviewed in Ref. [21]). Preclinical studies in vivo
attempted to identify which subtype of TNBC may
benefit from mTOR inhibitors. One study found that
everolimus had favorable activity against basal-like
subtype [27], but in another study, response to evero-
limus was not restricted to a specific TNBC subtype
[28].
Here, we aimed to identify selective genetic depen-
dencies impacting the fitness of the epithelial or mes-
enchymal phenotype breast cells, and to discover
actionable targets that improve the efficacy of either 5-
FU or everolimus in a phenotype-specific manner.
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2. Materials and methods
2.1. Cell culture
D492 and D492M cell lines were established as
described previously by Gudjonsson et al. [10] and Sig-
urdsson et al. [11], respectively. Briefly, a breast epithe-
lial progenitor cell line D492 was generated by
isolating the MUC1/EpCAM+ suprabasal cells from
normal primary tissue and immortalizing them with
HPV16-E6/E7 oncogenes [10]. Such immortalization
leads to inactivation of the p53 and Rb proteins (often
inactivated in BC), but does not compromise essential
functions of cell differentiation/polarization [29].
Therefore, the E6/E7 immortalized cell line has rele-
vance for studies on breast morphogenesis and BC, as
discussed previously [10,29]. D492 cells are progenitor
cells that can generate both luminal and myoepithelial
cells in culture and express several markers of both lin-
eages [10,12]. As accumulating evidence links progeni-
tor cells in the mammary gland to BC (reviewed in
Ref. [30]), D492 is an interesting cell model for BC
research.
When cocultured with breast endothelial cells in
Matrigel, the D492 cells spontaneously undergo EMT,
forming spindle-like colonies. The cells from a spindle-
like colony were isolated and clonally expanded giving
rise to the daughter cell line, D492M, which displays a
stable mesenchymal phenotype [11].
D492 and D492M cells were grown in H14 medium
as previously described [10,11]. Briefly, serum-free
DMEM-F12 medium [Thermo Fisher Scientific (TFS),
Waltham, MA, USA, 31331138] was supplemented
with penicillin and streptomycin (TFS, 15070-063),
250 ngmL1 insulin (Sigma, St.Louis, MO, USA,
I1882), 10 ngmL1 EGF (PeproTech, Cranbury, NJ,
USA, AF-100-15), 10 µgmL1 transferrin (Sigma,
T1147), 2.6 ngmL1 NaSel (BD Biosciences, San Jose,
CA, USA, 534201), 1010 M estradiol (Sigma, E2758),
500 ngmL1 hydrocortisone (Sigma, H0888), and
0.15 IU prolactin (Sigma, L6520). For passaging, cells
were detached using 0.25% trypsin-EDTA (TFS,
25200056), and trypsin was eventually inhibited by
adding soybean trypsin inhibitor (Sigma, T6522).
2.2. Drugs and reagents
5-FU (50 mgmL1, Accord Healthcare, London, UK)
was purchased from the pharmacy at the Radium
Hospital, Oslo University Hospital (Oslo, Norway),
everolimus (SML2282) and Fasnall (SML1815) were
purchased from Sigma-Aldrich, gefitinib (Iressa) was
purchased from Astra Zeneca, and S-trityl-L-cysteine
inhibitor STLC (2191) was purchased from Tocris
Biotechne (Abingdon, UK). SCH772984 (S7101) was
purchased from Selleck Chemicals (Houston, TX,
USA).
2.3. Protein expression analysis
The level of phenotype-specific proteins was measured
using a simple western immunoassay on a Peggy SueTM
instrument (ProteinSimple, San Jose, CA, USA). The
cells were lysed in lysis buffer (1% Triton X-100,
50 mM, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA,
100 mM NaF, 10 mM Na pyrophosphate, 1 mM
Na3VO4, 10% glycerol), supplemented with protease
and phosphatase inhibitors (Roche Applied Science,
Mannheim, Germany), followed by ultrasonication.
The concentration was adjusted to 0.8 lglL1. Pro-
tein separation was performed using a 12–230 kDa
separation master kit in accordance with the manufac-
turer’s protocol. Primary antibody incubation time
was adjusted to 60 min, while all the other settings
were kept on default. The COMPASS software
(ProteinSimple, version 2.7.1) was used to program the
experimental setup and to collect and analyze the data.
The following antibodies were used: anti-b-actin
(A5316, Sigma) 1 : 100, anti-E-cadherin (MAB1838,
R&D Systems, Minneapolis, MN, USA) 1 : 50, anti-
Cytokeratin 14 (NCL-L-LL002, Leica Biosystems, Buf-
falo Grove, IL, USA) 1 : 40, anti-cytokeratin 17
(M7046, Dako, Glostrup, Danmark) 1 : 40, anti-N-
cadherin (610920, BD Transduction Laboratories, San
Jose, CA, USA) 1 : 50, and anti-vimentin (550513, BD
PharMingen, San Diego, CA, USA) 1 : 50.
For high-throughput analysis (302 proteins), the cell
lysates were analyzed by reverse-phase protein array
(RPPA) at MD Anderson RPPA core facility (Hous-
ton, TX, USA). In brief, serial dilutions of the lysates
were arrayed on nitrocellulose-coated slides. A primary
antibody (specified at the core facility’s home page;
available upon request) was added to probe each slide,
followed by a biotin-conjugated secondary antibody.
A chromogenic reaction was used to detect the signal.
After scanning the slides, spot intensities were deter-
mined by analysis with the MICROVIGENE software (Vig-
eneTech, Carlisle, MA, USA). Each dilution series was
fitted with a logistic model (‘Supercurve Fitting’) to
obtain a dilution curve in log2 scale. The data in log2
scale were transformed to linear and median-centered
values for each protein. The signal for the protein of
interest was normalized to the signal of histone 3 in
each sample (the levels of histone 3 were similar
between the samples).
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2.4. Cell viability and proliferation assays
For experiments in adherent two-dimensional (2D) cell
cultures, 4000 cells were seeded in 96-well plates. D492
cell growth was monitored using the Incucyte instru-
ment (Essen BioScience, Hertfordshire, UK), which
tracks cell confluence over time. The viability was eval-
uated by measuring cell metabolic activity by CellTi-
ter-Glo (CTG) assay (Promega, Madison, WI, USA),
adding CTG directly to the wells (1 : 1). After 10 min,
bioluminescence was measured by VictorTM X3 Multi-
plate Reader (Perkin Elmer, Waltham, MA, USA).
For three-dimensional (3D) cultures in Matrigel,
2500 cells were suspended in 50 µL Matrigel (Corning,
Corning, NY, USA, 354230) and plated into the 96-
well plates (Corning, 10517742). After 30 min at
37 °C, 100 µL of EGM5 medium (Lonza, Basel,
Switzerland, CC-3162, containing 50 IUmL1 peni-
cillin, 50 µgmL1 streptomycin, hydrocortisone, FGF,
EGF, VEGF, R3-IGF-1, ascorbic acid, heparin, and
supplemented with 5% FBS) was added on top of the
Matrigel. The next day, the medium was replaced with
H14, and a day after, the drugs were added. The med-
ium with/without drugs was replaced every 3 days,
and after 8 days, cell viability was determined using
the CTG assay, when the medium was removed and
CTG was added directly on top of Matrigel (50 µL/
well). The plates were kept on a vigorous shaker for
1 h prior to the measurement of bioluminescence as
described above. In addition, the 3D colonies were
stained with the tetrazolium dye (Sigma, M5655) for
visualization. For that, the medium was removed,
50 µL of 0.4 mgmL1 dye was added, and after 1 h
at 37 °C the cultures were imaged using the GelCount
instrument (Oxford Optronix, Abingdon, UK).
2.5. Immunofluorescence
For staining of 3D colonies, the D492 and D492M
cells were seeded in drops of 50 µL Matrigel in cyto-
slides (Ibidi, Gr€afelfing, Germany) and incubated for
8 days in H14 medium. After fixation with 4%
paraformaldehyde (PFA, Chemi-Teknik, Oslo, Nor-
way) for 10 min, the colonies were stained with Alexa
FluorTM 546 phalloidin (Molecular Probes, Eugene,
OR, USA, #A22283, 1 : 40) to label F-actin. After
overnight incubation at 4 °C, the stained cultures were
washed and submerged in PBS before imaging.
For staining with anti-EGFR, the 2D cell cultures
on cytoslides were fixed in 4% PFA. The unspecific
binding was blocked with 10% horse serum for 1 h.
The cytoslides were stained with rabbit anti-EGFR
XP (Cell Signaling, Danvers, MA, USA, #4267)
diluted 1 : 50 in immunofluorescence buffer (PBS with
0.1% BSA, 0.2% Triton X-100, 0.05% Tween-20) sup-
plemented with 1% horse serum over night at 4 °C
followed by staining with donkey anti-rabbit DyLight
550 (Thermo Fisher, Waltham, MA, USA) for 1 h.
The cytoslides were mounted with ProLongTM Gold
Antifade Reagent with DAPI (Invitrogen, Carlsbad,
CA, USA, #P-36931) before imaging.
The imaging was performed using laser scanning
confocal microscope (LSM710; Carl Zeiss, Oberko-
chen, Germany), equipped with Plan-Apochromat
963/1.4 Oil DICIII objective for 2D images and EC
Plan-Neofluar 910 objective for 3D cultures. Image
processing and visualization were performed by using
the ZEN LIGHT 2011 software (Oberkochen, Germany).
2.6. Flow cytometry
D492 and D492M cells were collected on ice, fixed for
10 min in 1.6% PFA, and permeabilized in 100% ice-
cold methanol. Control and drug-treated samples were
stained at room temperature for 30 min with varying
concentrations of Pacific Orange dye (TFS) ranging
from 0 to 2 nglL1 for barcoding of the samples.
Subsequently, the samples were washed and pooled for
staining with anti-phospho-S6 Alexa 647 (Cell Signal-
ing Technology, #4851 dilution 1 : 200) for 30 min at
room temperature.
For cell cycle analysis, the cells were stained with
20 µgmL1 Hoechst 33342 (Life Technology, Carls-
bad, CA, USA, #H3570) for 60 min at 37 °C. The
samples were analyzed on an LSR II flow cytometer
(BD Bioscience). BD FACSDivaTM and FLOWJO soft-
ware (FlowJo, Ashland, OR, USA) were used to col-
lect and analyze the data.
2.7. Preparation of the CRISPR library and
lentiviral production
The ‘druggable genome’ CRISPR knockout library
(described previously [31,32]) was generously provided
by K. C. Wood (Duke University, NC, USA). This
pooled library consists of lentiviral plasmids (Lenti-
CRISPR V2), each encoding a single-guide RNA
(sgRNA), the CRISPR-associated nuclease (Cas9), and
a gene conferring resistance to puromycin. sgRNAs
facilitated targeted introduction of double-strand
DNA breaks by Cas9 into the coding regions of the
genes of interest. Five unique sgRNA constructs were
chosen targeting 2240 genes encoding for all members
of the protein kinome, chromatin modifiers, regulators
of the DNA damage response, targets of FDA-ap-
proved drugs for any indication, proteins mutated in
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cancer, and components of pathways dysregulated in
tumorigenesis, tumor maintenance, and drug resis-
tance.
The library was cloned and prepared as previously
described [33]. Library DNA stock was amplified in
Lucigen 10G ELITE Electrocompetent bacteria and
cultured on agar plates to achieve at least one million
distinct colonies. The colonies were collected, and the
DNA was isolated using a Midi Kit (Qiagen, Hilden,
Germany).
The lentivirus carrying the library was generated in
HEK293T cells. HEK293T cells were seeded at
5 9 10⁶ in a T75 culture flask in DMEM supple-
mented with 10% FBS. The next day, a transfection
mix consisting of 9 µg packaging plasmid Pax2, 3 µg
envelope plasmid Pmd2G, and 15 µg CRISPR library
was prepared in 200 µL Opti-MEM (Gibco, Paisley,
UK). In a separate tube, FuGENE transfection
reagent (Promega, Madison, WI, USA) was added to
1 mL of Opti-MEM at 1 : 13 dilution. After a 30-min
incubation, the contents of both tubes were combined
and added to the HEK293T cells in serum-containing
medium. Following an overnight incubation, the med-
ium was replaced with DMEM containing 20% FBS.
Two days later, the medium containing lentivirus was
collected, centrifuged at 200 g for 5 min, and filtered
through a 0.45-µm filter. The virus stock [after detec-
tion of multiplicity of infection (MOI) using standard
protocols] was stored at 80 °C until further use.
2.8. CRISPR loss-of-function screen
The screen was conducted by first plating 5 9 105
D492 and D492M cells per well into 25 6-well plates.
The following day, virus at MOI of 0.2 and polybrene
(8 µgmL1) were added to the cells. Plates were cen-
trifuged at 800 g for 1 h and incubated overnight at
37 °C. One day after lentiviral transduction, the trans-
duction medium was replaced with fresh medium con-
taining puromycin at 2 µgmL1. One day later, the
surviving cells were trypsinized and re-plated on 500-
cm2 culture plates. Simultaneously, an initial sample
(T0) was flash-frozen in liquid N2. Cells were propa-
gated in the presence of puromycin for 7 days to allow
complete DNA alternation. At that point, cells were
split into two replicate treatment groups—1 µM 5-FU
or 5 nM everolimus drug or DMSO control—with
12 9 106 cells per condition. Simultaneously, a (T7)
sample was flash-frozen. The cells were continuously
cultured in the presence of 5-FU, everolimus, or
DMSO vehicle for an additional two or four weeks
before the cells were collected and flash-frozen. Cells
were split as necessary to maintain sub-90%
confluency and no fewer than 12 9 106 cells to main-
tain sequence diversity.
Genomic DNA was isolated and prepared for
sequencing as previously described [33]. Briefly, at least
10 million cells were processed to extract total genomic
DNA (Qiagen Blood and Tissue DNA Extraction
Kit). The samples were cleaned by ethanol precipita-
tion, and then run in two subsequent PCR steps as
described in Ref. [33], with the PCR step 1 consisting
of eight parallel 100 µL reactions of 5 µg DNA each,
and step 2 adding a condition-specific barcode
sequence for subsequent deconvolution. The entire
PCR product from the second reaction step was run
through a 2% agarose gel and extracted using a Gel
Extraction Kit (Qiagen), ethanol precipitated, and its
concentration tested with a Qbit (Life Technologies).
Sequencing was performed on an Illumina NextSeq
500 (San Diego, CA, USA) with 75bp, single-end
reads. A final concentration of 3 pmol DNA was
loaded with a PhiX spike of greater than 15% to
enhance signal complexity.
2.9. Data analyses
Sequence counts were deconvolved to separate treat-
ment groups from total sequence reads, and then,
sgRNA reads were counted for each construct as pre-
viously described [33]. To analyze samples using RSA
(redundant siRNA analysis), the number of counts for
each construct was normalized to the total number of
counts in the same sample and averaged across both
replicates. By comparing the number of cells contain-
ing each sgRNA in the D492 and D492M cells, we
determined the relative effect on viability that each
sgRNA had in one cell line with respect to the other.
By comparing the number of cells containing each
sgRNA in the drug-treated versus nontreated cells, we
determined the relative effect on viability that each
sgRNA had in combination with the treatment. Genes
were ranked and assigned significance using RSA [34].
For screen analysis using MAGeCK (model-based
analysis of genome-wide CRISPR-Cas9 knockout), we
ran MAGeCK using MLE (maximum-likelihood esti-
mation) with treatment-deconvolved FASTQ files, nor-
malized to control (nontargeting) sgRNA [35,36].
Screen and sequence quality analysis was provided by
MAGeCK-VISPR.
Heat maps were designed using the R plugin pheat-
map. Qiagen Ingenuity Pathway Analysis (IPA) was
used to determine pathway enrichment in the hit lists.
The hits were used as input for STRING visualization
[37]. A network of direct protein—protein interactions
was built based on the highest confidence (0.9)
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evidence, and functional enrichment (KEGG/Reac-
tome pathways) was determined using the STRING
web tool (http://www.string-db.org).
3. Results
3.1. D492 and D492M cells carry distinct
phenotypes
To validate that D492 and D492M cells retain their
previously described characteristics reflecting epithelial
and mesenchymal phenotypes, respectively, we first
analyzed the expression of known markers. In agree-
ment with previous studies [10–12], we determined that
D492 cells express high levels of epithelial markers
such as E-cadherin and cytokeratins, while the D492M
cells lost the expression of these proteins and gained
expression of mesenchymal markers, including N-cad-
herin, vimentin, and several others (Fig. 1A,B). When
testing cell proliferation in 2D cultures, we observed
faster growth of D492 cells compared with D492M
(Fig. 1C), which is a common difference for their
respective phenotypes. When cultured in 3D Matrigel,
D492 forms branching lobular-like structure character-
istic for epithelial cells, whereas D492M shows invasive
behavior typical for mesenchymal-like cells (Fig. 1D).
Altogether, this confirms that D492 cells represent the
epithelial faster-growing phenotype, while D492M cells
display the mesenchymal invasive phenotype.
3.2. Determining sensitivity of D492 and D492M
cells to 5-FU and everolimus
Because our CRISPR screen in the presence of ‘ther-
apy pressure’ would require continuous treatment with
the drug for up to four weeks, we set out to determine
sublethal drug doses. Dose–response studies in 2D cul-
tures revealed that a 3-day treatment with 5-FU up to
10 µM reduced cell viability by approximately 10% in
both cell lines (Fig. 2A). Tracking cell density over a
6-day period confirmed that a dose of 1 µM 5-FU
reduces cell proliferation in a statistically significant
manner (Fig. S1A). This dose caused approximately
10% reduction in viability when the cells were cultured
in Matrigel in 3D and treated for 8 days (Fig. 2B).
Based on these data, a 1 µM dose of 5-FU was selected
to be used in the CRISPR screen.
A 3-day treatment with everolimus up to 100 nM
reduced cell viability in 2D cultures by 20–30%
(Fig. 2C). D492M cells seemed to be slightly more sen-
sitive than D492, although the difference was not sta-
tistically significant. However, an 8-day treatment with
5 nM everolimus in 3D cultures in Matrigel confirmed
a higher sensitivity of D492M cells, whose viability
was reduced by approximately 35% compared with
15% in D492 cells (Fig. 2D). Further, 5 nM everolimus
suppressed the mTOR signaling pathway as detected
by decreased phosphorylation of its downstream tar-
get, S6 ribosomal protein, and no further decrease in
phospho-S6 levels was observed with higher doses of
everolimus (Fig. 2E). The effect of everolimus on
phospho-S6 was stronger in D492M cells. The higher
sensitivity of D492M cells might be attributed to their
dependence on mTOR signaling. Indeed, the protein
levels of mTOR and its downstream targets were
higher in D492M cells compared with D492
(Fig. S1B), which is in line with the previous reports
that link PI3K-AKT-mTOR signaling to EMT
[23,38,39]. Based on these data, we chose to use 5 nM
of everolimus for both cell lines in the CRISPR
screen.
3.3. CRISPR screen uncovers genetic
vulnerabilities specific for D492 or D492M cells
We first sought to identify phenotype-specific suscepti-
bilities to single-gene knockout. We employed the
D492 and D492M cells and conducted a pooled
CRISPR loss-of-function screen of 2240 genes in the
‘druggable genome’ targeting the entire human
kinome, targets of FDA-approved drugs, cancer-re-
lated pathways, DNA damage repair genes, chromatin
modifiers, and components of pathways dysregulated
in tumorigenesis, tumor maintenance, and drug resis-
tance. We employed the focused library because our
hits could eventually be validated using existing tar-
geted inhibitors, and would have a better potential for
therapeutic implementation. We used lentiviral trans-
duction to introduce barcoded sgRNA-containing plas-
mids into cells, cultured for 7 days under puromycin
selection to permit time for DNA editing. Then, the
samples were split into treatment groups (two repli-
cates per group) to receive DMSO vehicle or continu-
ous drug treatment for two or four weeks. Samples
were collected at time points as shown in Fig. 3A, and
the number of each barcoded sgRNA remaining at
each time point was counted using next-generation
sequencing (Table S1). We used the MAGeCK-VISPR
automated CRISPR screen analysis tools to determine
sequencing quality (Fig. S2A–F). The Pearson correla-
tion between sample replicates was high, and matching
time points and treatments generally grouped together
(Fig. S2G), revealing good reproducibility.
We first determined genetic vulnerabilities at the T7
time point, and DMSO controls at week 2 and week 4
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time points. To determine the overall effectiveness and
significance of each gene, taking into account the dif-
fering knockdown efficiency and activities of each of
the five sgRNAs targeting it, we compared the results
of two distinct analysis methods. We first used RSA to
score hits based on the collective fold-change activity
of the entire sgRNA set for each gene and assign a P-


























































































































































































































































































Fig. 1. D492 and D492M cells carry an epithelial and a mesenchymal phenotype, respectively. (A, B) Relative protein levels of phenotype-
specific markers in D492 and D492M cells as measured by simple western immunoassay (A; representative electropherograms, where the
x-axis shows the protein size (kDa), and the y-axis indicates signal intensity, reflecting the amount of the protein), and the RPPA (B;
average  SD from three technical replicates). (C) Cell growth shown as increase in confluence (y-axis) during time after seeding (x-axis)
tracked by the Incucyte (average  SEM, n ≥ 3). (D) D492 and D492M cell colonies formed during 8-day growth in 3D Matrigel and stained
with phalloidin (red) for labeling F-actin; scale bar, 50 µm.
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RSA-identified hits to those generated by MAGeCK-
MLE (Table S2). MAGeCK-MLE automates sample
normalization and comparison between T0-, DMSO-,
and drug-treated samples to determine a beta score,
where negative beta score indicates sensitivity to loss
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Fig. 2. Sensitivity of D492 and D492M cells to 5-FU and everolimus. (A) D492 and D492M cells growing in 2D were treated with increasing
concentration of 5-FU for 3 days before the cell survival was measured by the CTG assay; average  SD (n = 2). (B) Viability of D492 and
D492M cells in 3D Matrigel treated with 1 µM 5-FU for 8 days before the cell survival was measured by the CTG assay; average  SEM
(n ≥ 8). (C) D492 and D492M cells growing in 2D were treated with increasing concentration of everolimus for 3 days before the cell
survival was measured by the CTG assay; average  SEM (n ≥ 4). (D) Viability of the D492 and D492M cells in 3D Matrigel treated with
5 nM everolimus for 8 days before the cell survival was measured by the CTG assay; average  SEM (n ≥ 9). (E) Reduction in the level of
phospho-S6 (as measured by flow cytometry) in D492 and D492M cells in response to 2 days of treatment with indicated concentrations of
everolimus; left: representative histograms; right: relative level of phospho-S6 quantified by normalizing the levels in the treated samples to
the levels in the nontreated respective controls (set to 100); average  SEM (n = 3); *P ≤ 0.05, unpaired t-test.
Fig. 3. CRISPR screen-identified gene knockouts specifically toxic to D492 or D492M cells. (A) Schematic of the CRISPR loss-of-function
screening strategy. (B, C) Heat maps of the knockouts significantly more toxic to D492 compared with D492M (B) or D492M compared
with D492 (C) with the significance level logP ≤ 3 in either two- or four-week samples, as calculated using RSA. Color intensity indicates
logP values. Red dots indicate selective hits that were also found using the orthogonal CRISPR analysis tool MAGeCK-MLE. (D, E) STRING
interaction network of the toxic knockouts specific for D492 (D; red and blue indicate proteins involved in ERBB and GnRH signaling,
respectively) or D492M (E; red and blue indicate proteins involved in cell cycle/mitosis and RNA metabolism/spliceosome, respectively); the
panels below indicate KEGG/Reactome pathways enriched in the D492- or D492M-specific hit lists; FDR, false discovery rate.
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sgRNA construct relative to the initial T0 condition
for that cell line would indicate the loss of an essential
fitness gene over time (a measure of gene ‘depen-
dency’). If the ratio of counts for a sgRNA construct
decreases between two conditions (treated vs. untreated
or one cell line vs. the other), that indicates a condi-
tion-specific essential gene.
To determine which genes were toxic in the short
term when silenced, we first used RSA and identified
the essential genes lost by the T7 time point for each
cell line. As expected, a number of gene knockouts
(such as CDK1, PLK1, and WEE1) centering on cell
cycle, DNA repair, and RNA synthesis pathways were
toxic to both cell lines (Fig. S3A). However, a large
number of knockouts were selectively toxic indicating
that D492 and D492M exhibit unique phenotype-asso-
ciated dependencies.
The Cancer Dependency Map (DepMap) conducted
CRISPR-Cas9 gene knockouts on hundreds of human
cancer cell lines to profile their dependency on these
genes (publically available at DepMap portal). We
compared our most essential genes, as calculated by
RSA, to the median essentiality score for each gene
across all BC cell lines in DepMap (DepMap, Broad
(2020): DepMap 20Q4 Public.figshare. Dataset https://
doi.org/10.6084/m9.figshare.13237076.v1) [40]. We
found excellent agreement for essentiality at the T7
time point (Fig. S3B,C), thus confirming our screen
had identified known essential genes in BC.
We next cultured each cell line with continuous
treatment of DMSO vehicle, 5-FU, or everolimus for
an additional 2 or 4 weeks to identify long-term gene
knockouts that are selectively toxic to each phenotype
alone or when combined with the drug treatment.
First, we compared the dependency of DMSO-treated
D492 and D492M cells as calculated by MAGeCK to
the median DepMap score, and again saw a high
degree of overlap as evidenced by our hits weighted
toward the most essential genes in DepMap for BC
(Fig. S4A). To gain further confidence that our screen
was identifying known essential genes, we calculated a
precision/recall plot for all DMSO-treated conditions
at both time points using the list of essential and
nonessential genes published by Hart et al. [41]
(Fig. S4B). We saw excellent precision/recall of essen-
tial and nonessential genes, as evidenced by a long
straight run and linear decrease in precision as recall
approaches 1.0.
We noted a strong time-dependent effect on gene
dependency. Most essential genes (those which caused
a greater than twice standard deviation reduction in
beta score by MAGeCK) could broadly be classified
into those causing dependency at mid- or late time
points (Fig. S5A,B and Table S3), which agrees with
prior literature on the time-dependent association with
gene dependency in CRISPR screens [42]. In general,
essentiality scores for D492 cells reached the highest
levels, that is, lowest beta score at the mid-time point
(21 days after CRISPR knockout, the ‘Week 2’ sam-
ple) (red and green clusters in Fig. S5A). In contrast,
beta scores for many essential genes in the D492M
cells continued to decrease to the late time point
(35 days, the ‘Week 4’ sample) (green and blue clusters
in Fig. S5B). Again, this suggests differences in depen-
dency between D492 and D492M cells. Reactome and
Kegg pathway over-representation analysis (ORA)
suggested that many pathways, including cell cycle,
mitotic/cell division, DNA synthesis and repair, and
mRNA slicing, were more significantly enriched at the
mid- and late time points compared with the early time
point (Fig. S5C).
To discover mid/long-term knockouts that are selec-
tively toxic to each phenotype in the absence of drugs,
we compared the gene dependencies of D492 versus
D492M, and vice versa, defining hits as those with a
logP ≤ 3 significance by RSA (Fig. 3B,C). These hits
represent selective essentiality, namely that the indi-
cated genes are specifically critical for one phenotype
over the other. For increased confidence, we repeated
this analysis using MAGeCK-MLE (Fig. S6A,B), and
we noted substantial overlap in the selectively essential
genes identified using both methods (red marks in
Fig. 3B,C and Fig. S6C–F).
Protein–protein interaction networks and KEGG/
Reactome-enriched pathways revealed vulnerability
nodes specific to each phenotype (Fig. 3D,E). For
D492 cells, we identified the EGFR-SRC node,
involved in GnRH signaling and ErbB signaling that
were found among the top 3 KEGG pathways
enriched in this dataset (Fig. 3D). Of note, EGFR was
also found by RSA among the short-term knockouts
specifically toxic to D492 cells (Fig. S3A). While the
MAGeCK method did not mark EGFR itself as a
selective hit, the EGFR-activated RAS-MAPK signal-
ing cascade was identified as a vulnerability node, with
KRAS, HRAS, RAF1, MAP2K1, MAPK1, and
MAP2K4/5, all more essential to D492 cells compared
with D492M (Fig. S7A). Notably, the expression level
of EGFR was also considerably higher in D492 cells
than D492M (Fig. S7B).
A similar analysis of the D492M-specific hits
revealed a network dominated by proteins involved in
cell cycle and RNA metabolism (Fig. 3E). Genes
encoding several of the highest-scoring interacting pro-
teins (CCNB1, CCNH, BUB1B, MNAT1) are involved
in the G2-M cell cycle transition. Of note, there was
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no significant difference in cell cycle distribution
between D492 and D492M cells (Fig. S7C). Genes
encoding another distinct node of interacting proteins
(PRPF8, DDX46, XAB2, RBMX, CDC5L) are associ-
ated with RNA splicing. Among the D492M-specific
knockouts, we also found well-known regulators of
EMT, such as genes related to transforming growth
factor-beta (TGF-b) signaling, TGFBR1 and TGFBR2
(Fig. 3C,E).
Next, we determined how drug treatment would
affect genetic vulnerabilities. We compared 5-FU or
everolimus-treated cells to their respective DMSO con-
trols, revealing the knockouts that induce a greater
loss of viability in the presence of the drug. We identi-
fied drug sensitizers as genes with a LogP ≤ 3 signifi-
cance by RSA. Figure 4 shows all genes that were hits
in at least one condition. In general, most hits were
exclusive to either D492 or D492M cells, indicating
phenotype-dependent drug sensitization. Furthermore,
in both cell lines, most of the hits were selective for 5-
FU and everolimus, suggesting a drug-dependent sensi-
tization. Among the few knockouts that significantly
potentiated the effect of both drugs were EGFR in
D492 cells and fatty acid synthase (FASN) in D492M
(‘Ev/5-FU’ clusters in Fig. 4, also found as a hit by
MAGeCK, Fig. S8). Not only the knockout of EGFR
itself but also several other genes related to the
EGFR-activated RAS-MAPK signaling pathway (like
RAF1 and MAPK1) potentiated the drugs more signif-
icantly in D492 cells compared with D492M (Fig. S9).
Regarding FASN, our RPPA analysis revealed three-
fold higher expression of FASN protein in D492M
cells compared with D492 (Fig. S10). FASN was also
found among the D492M-specific short-term essential
genes (Fig. S3A). Collectively, this suggests the impor-
tance of FASN for D492M cells, particularly under
‘therapy pressure’.
3.4. Phenotype-specific genetic vulnerabilities
represent actionable targets
To confirm that the identified genetic vulnerabilities
represent phenotype-specific targets for therapy, we
tested the effect of inhibitors of EGFR, cell cycle pro-
gression, and FASN alone and in combination with
everolimus or 5-FU. We used 3D cell cultures in
Matrigel that are considered to be a more representa-
tive model for testing therapies and where prolonged,
8-day treatment could be performed [43].
To target EGFR, we applied gefitinib, a clinically
approved inhibitor of the EGFR tyrosine kinase
domain. Gefitinib alone induced a dose-dependent








































Fig. 4. Gene knockouts sensitizing D492 or D492M cells to either
5-FU or everolimus. Gene knockouts that are more toxic in
combination with either 1 µM 5-FU or 5 nM everolimus (Ev) after
four-week treatment; all genes where logP ≤ 3 by RSA in at least
one condition are shown; color intensity indicates logP values. The
gene clusters sensitizing to 5-FU, Ev, or both (Ev/5-FU) specific for
each cell line are indicated on the right.
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compared with D492M cells (Fig. 5A and Fig. S11A).
Of note, D492 cells were also more sensitive to the
ERK inhibitor SCH772984 that targets the MAPK
signaling pathway downstream from EGFR
(Fig. S11B). Inhibition of EGFR in the presence of
everolimus resulted in a significantly higher antiprolif-
erative effect than either treatment alone, and the total
effect was stronger in D492 cells than in D492M
(Fig. 5B). Similar results were observed when gefitinib
was combined with 5-FU (Fig. S12A). Thus, pharma-
cological inhibition of EGFR or ERK impacted cell
viability in line with the CRISPR results, suggesting
that EGFR-RAS-MAPK signaling cascade is more
important for the epithelial phenotype cells in the
absence and presence of ‘therapy pressure’.
To block the G2-M cell cycle transition, we used an
inhibitor of kinesin 5 (EG5). Although EG5 was not
included in the CRISPR screen, EG5 is a critical medi-
ator of the G2-M transition and therefore a good tar-
get to disrupt this process. EG5 drives the microtubule
assembly during the mitotic spindle formation [44],
and EG5 inhibitors, such as S-trityl-L-cysteine (STLC),
prevent correct spindle organization, leading to the cell
cycle arrest in G2-M [45]. Here, we show that D492M
cells are more sensitive to the treatment with STLC
than D492 cells (Fig. 6A). Furthermore, in D492M
cells a combination of STLC and everolimus resulted
in a greater antiproliferative effect compared with
either treatment alone, which was not the case in D492
cells (Fig. 6B). However, we did not observe a clear
benefit of adding STLC to 5-FU (Fig. S12B). This
could be explained by the fact that 5-FU acts on divid-
ing cells, and STLC interrupts cell division. Taken
together, these findings suggest that the EG5 inhibition
selectively impacts growth in the mesenchymal-like
cells and may sensitize them to targeted drugs, such as
everolimus.
To target FASN, we used Fasnall, a selective inhibi-
tor that has shown a potent antitumor activity in BC
models [46]. FASN knockout was identified as a sensi-
tizer to the drugs in D492M cells, and FASN protein
expression was higher in D492M, suggesting the
importance of FASN for survival of the mesenchymal
cells. However, we did not observe a higher sensitivity
to FASN inhibition with Fasnall in D492M cells. On
the contrary, D492 cells were more vulnerable to the
used doses of Fasnall (Fig. 7A). However, in line with























































Control Ev Gef Ev+Gef 
Fig. 5. Sensitivity of D492 and D492M
cells to the EGFR inhibitor gefitinib. The
cells were grown in 3D Matrigel and
treated for 8 days with the indicated
concentrations of gefitinib alone (A) or in
combination with 5 nM everolimus (B)
before the cell survival was measured by
the CTG method; average  SEM [n ≥ 6
(A), n = 3 (B)]; the representative pictures
of the D492 cell colonies are shown in the
lower panel; * and **, P ≤ 0.05 by
unpaired and paired t-test, respectively.
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of Fasnall in D492M was enhanced by combination
with the drugs (Fig. 7B and Fig. S12C), whereas there
was no significant improvement in D492 cells.
In summary, by applying a CRISPR-Cas9 loss-of-
function screen, we detected phenotype-specific vulner-
ability genes in the absence or presence of clinically
relevant therapy. The identified genetic vulnerabilities
pinpoint actionable targets that can be used to design
combinatorial treatments to target cells of distinct phe-
notypes.
4. Discussion
The goal of this study was to detect therapeutic vul-
nerabilities unique to either the epithelial or mesenchy-
mal phenotype in breast epithelial cells by using a
CRISPR-Cas9 genetic loss-of-function screen. Previous
studies have employed a similar approach in a range
of cancer cell lines to identify genotype-specific vulner-
abilities and promising therapeutic targets [40,47–49].
To the best of our knowledge, this is the first study
that employs such a screen in isogenic cell lines dis-
playing opposing phenotypes on the EMT spectrum.
Both the CRISPR screen and the validation analyses
with targeted inhibitors suggest that the epithelial phe-
notype is more sensitive to disruption of EGFR and
the downstream RAS-MAPK signaling pathway, while
the mesenchymal phenotype is more susceptible to dis-
ruption of the G2-M cell cycle transition. The associa-
tion between EGFR and the epithelial phenotype has
been observed previously, where introduction of
EGFR into the mesenchymal-like D492 cells reversed
them into the epithelial state [50]. Furthermore, com-
putational approaches predicted a higher flux through
the EGFR and RAS-MAPK signaling network in
D492 cells, and the genes from these pathways were
predicted to reverse D492M into D492 phenotype [51].
It has also been demonstrated that acquisition of the
mesenchymal features reduces sensitivity to EGFR
inhibitors [52,53]. This is in line with our observation
that gefitinib was more potent in D492 cells than
D492M. Furthermore, EGFR knockout and gefitinib
sensitized D492 cells to everolimus or 5-FU leading to
a stronger antiproliferative effect than what was
achieved in D492M. Taken together, these results sug-

























































Fig. 6. Sensitivity of D492 and D492M
cells to the G2-M inhibitor STLC. The cells
were grown in 3D Matrigel and treated
for 8 days with the indicated
concentrations of STLC alone (A) or in
combination with 5 nM everolimus (B)
before the cell survival was measured by
the CTG method; average  SEM [n ≥ 6
(A), n ≥ 3 (B)]; the representative pictures
of the D492M cell colonies are shown in
the lower panel; * and **, P ≤ 0.05 by
unpaired and paired t-test, respectively.
2038 Molecular Oncology 15 (2021) 2026–2045 ª 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies
CRISPR screen in an EMT pair of breast cells A. Barkovskaya et al.
EGFR and the downstream RAS-MAPK signaling
pathway that represent therapeutic vulnerabilities and
could be exploited as targets in combination therapies.
Identification of the G2-M transition as a vital node
in the mesenchymal phenotype also agrees with the
previous studies. It has been reported that G2-M arrest
by the anti-microtubule drug paclitaxel or inhibition of
aurora kinases prevented mesenchymal transition
[54,55]. Furthermore, we also identified loss of
AURKA, encoding the aurora kinase A, to be more
toxic to the D492M cells than D492 (Table S3). Based
on these data, further investigation of clinically rele-
vant G2-M inhibitors for targeting the mesenchymal
phenotype could be suggested. Of note, a clinical trial,
where the aurora kinase A-selective inhibitor alisertib
was used in combination with paclitaxel, revealed a
therapeutic benefit of adding alisertib in advanced BC
[56].
In addition, we identified knockouts of TGF-b
receptors (TGFBRs) and RNA splicing machinery as
selectively toxic for the mesenchymal-like cells. These
observations are in line with what is known about
their association with EMT. TGF-b is a known indu-
cer of EMT in advanced cancers [57]. Furthermore,
increase in TGFBR expression and signaling has been
linked to taxane resistance, and treatment with
TGFBR inhibitors could prevent both EMT and
chemoresistance in breast cancer [58]. Notably, EMT
has also been linked to alternative splicing in breast
cancer [59]. Although it is an interesting observation
with potential prognostic value, it does not represent a
therapeutically tractable target.
In search of genes whose loss is selectively toxic to
the mesenchymal phenotype under ‘therapy pressure’,
we identified FASN. By combining the FASN inhibi-
tor Fasnall with everolimus, we confirmed this finding
in D492M cells. FASN is an attractive therapeutic tar-
get, since it is overexpressed in tumor cells compared
with normal cells [60]. FASN modulates cellular ener-
getics and membrane architecture, thereby influencing
oncogenic signaling and sustaining cancer cell growth
and survival [61]. FASN expression has been shown to
correlate with BC progression, resistance, and poor


























































Fig. 7. Sensitivity of D492 and D492M
cells to the FASN inhibitor Fasnall. The
cells were grown in 3D Matrigel and
treated for 8 days with Fasnall alone (A)
or in combination with 5 nM everolimus
(B) before the cell survival was measured
by the CTG method; average  SEM
(n ≥ 3) except for 20 µM in A,
where  SD (n = 2); the representative
pictures of the D492M cell colonies are
shown in the lower panel; * and **,
P ≤ 0.05 by unpaired and paired t-test,
respectively.
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expected to be linked to EMT/mesenchymal pheno-
type, as shown by others [63], and also detected in the
D492M cells. The latter coincides with the higher flux
of fatty acid oxidation and the different lipid profile in
D492M cells, as shown previously [64,65]. Altogether,
this suggests that EMT is associated with changes in
lipid metabolism and that cells of the mesenchymal
phenotype are sensitive to intervention within this
metabolic system. In contrast to what could be
expected, we detected lower sensitivity to the FASN
inhibitor Fasnall in D492M cells than D492. This
might be due to higher endogenous expression of the
FASN protein and, thus, incomplete pharmacological
inhibition in D492M cells. Notably, FASN knockout
was also found among the D492M-specific short-term
vulnerabilities, arguing for FASN as an actionable tar-
get in the mesenchymal phenotype, particularly in
combination with clinically used anticancer drugs.
The findings presented here are based on D492 and
D492M cells that are nontumorigenic. However, D492
cell model shows similarities to TNBC, due to their
native basal cell phenotype, stem cell-like properties,
lack of expression of hormone receptors, and HER2
and ability to undergo EMT. Therefore, our findings
could be relevant to TNBC that demonstrates high
degree of phenotypic heterogeneity and could benefit
from phenotype-tailored combination therapies.
5. Conclusion
Our findings support the application of a CRISPR
genetic loss-of-function screen as an effective strategy
to identify phenotype-specific therapeutic vulnerabili-
ties. The disclosed genetic vulnerabilities pinpoint
actionable targets and suggest inhibitors for combina-
tion therapies that can target distinct phenotypes.
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Fig. S1. Effect of 5-FU on cell growth and the level of
mTOR signaling-related proteins. A, Cell confluence
(tracked by Incucyte, left panel) in D492 cultures in
2D treated with indicated concentration of 5-FU; right
panel: relative cell density in the treated samples nor-
malized to the nontreated controls (set to 100); average
+/-SEM (n = 6); * p ≤ 0.05, unpaired t-test; B, Rela-
tive levels of mTOR and its downstream target (phos-
pho)proteins as detected by RPPA in D492 and
D492M cells; average +/- StDev from three technical
parallels.
Fig. S2. CRISPR screen sequencing and replicate qual-
ity analysis. A, Distribution of mean sequence quality.
B, Distribution of GC content. C, Mapping ratio of
all reads for indicated conditions. D, Gini index. E,
Number of zero-count sgRNAs per sample. F, normal-
ized read count distribution, plotted as mean with 10-
90 percentile whiskers. G, Heat map of Pearson corre-
lation scores for all CRISPR screen samples with
unsupervised clustering.
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Fig. S3. Short-term vulnerability genes in D492 and
D492M cells overlap with DepMap dependency. A,
Short-term gene essentiality was determined using
RSA by taking the ratio of sgRNA construct represen-
tation at the T7 time point compared to T0. All genes
where the logP significance was ≤-2 are shown (EGFR
and FASN are indicated); color intensity indicates
logP values. B and C, The median DepMap gene
essentiality score with CRISPR knockout (CERES
score) across breast cancer cell lines is shown for every
gene in the CRISPR library. Negative scores indicate
increasing dependency on that gene. Red highlighted
points are essential genes identified in (A) for the indi-
cated cell line.
Fig. S4. Mid/long-term vulnerability genes in D492
and D492M cells compared to the Cancer Dependency
Map. A, DepMap CERES gene dependency scores
shown for each gene in the CRISPR library. Red high-
lighted points indicate genes found to be essential to
the indicated cell lines at either week two or week
four, with hits defined as genes having scores greater
than three standard deviations from the mean using
MAGeCK-MLE. B, Precision/recall plot for D492 and
D492M cells after two or four weeks DMSO treatment
of previously published in Hart et al. [41] known
essential genes compared to non-essential genes.
Fig. S5. Time influence on gene essentiality. A and B,
Genes in D492 (A) and D492M (B) cells were defined
as ‘essential’ if their beta score decreased by two or
more standard deviations from the mean at an early
(7d), mid (21d), or late (35d) time point. Using unsu-
pervised clustering, genes separated into distinct
groups: mid-(highly)essential, where gene dependency
reached maximum at day 21 and did not change fur-
ther with time; late-(highly)essential, where dependency
increased with time and reached maximum at the final
time point, day 35d; the ‘variable/weak essential’ clus-
ter included genes, whose essentiality was observed
only at a single time point, was weak and did not
increase over time. C, Representative enriched Reac-
tome and Kegg pathways using Over-Representation
Analysis (ORA) for D492 and D492M cell lines at
indicated time points.
Fig. S6. Phenotype-selective genes identified from
CRISPR screen using MAGeCK-MLE. A and B,
After two weeks (A) or four weeks (B) of DMSO vehi-
cle treatment, sgRNAs targeting indicated genes may
be either depleted or enriched. Phenotype-selective
gene essentiality consists of genes with greater deple-
tion in one cell line compared to the other. Shown is
the beta score as calculated using MAGeCK-MLE.
The top 15 genes in each category are labeled. C-F,
Beta scores given by MAGeCK-MLE for indicated
conditions shown with RSA hits (logP ≤ 3) high-
lighted in red, which are weighted towards the more
essential genes as ranked by MAGeCK-MLE.
Magenta-highlighted genes are previously published
non-essential genes [41].
Fig. S7. Comparison of the significance of the EGFR
signaling-related gene knockouts, EGFR protein levels
and cell cycle distribution in D492 and D492M cells.
A, Heat map of MAGeCK-MLE results for D492 and
D492M cells for EGFR-RAS-MAPK signaling related
genes. B, Immunofluorescence pictures indicating
EGFR protein level; scale bar, 20 µm. C, DNA con-
tent indicating cell cycle distribution in D492 and
D492M cells as detected by flow cytometry.
Fig. S8. Phenotype-specific gene cooperativity with
everolimus and 5-FU identified using MAGeCK-MLE.
CRISPR hits for everolimus (A, C) and 5-FU (B, D)
treated cells in indicated cell lines. Phenotype-specific
gene essentiality consists of genes with greater deple-
tion in one cell line compared to the other. Shown is
the beta score as calculated using MAGeCK-MLE.
The top 15 genes in each category are labeled.
Fig. S9. The significance of EGFR signaling-related
gene knockouts for toxicity in cells under ‘therapy
pressure’. LogP values for EGFR signaling related
genes (defined by Ingenuity Pathway Analysis) in ever-
olimus- or 5-FU- treated versus nontreated D492 or
D492M cells at week two or week four.
Fig. S10. FASN protein expression in D492 and
D492M cells. FASN expression level was detected by
RPPA (average +/- StDev from three technical paral-
lels).
Fig. S11. Sensitivity of 2D cultures of D492 and
D492M to the EGFR and ERK inhibitors. Cells were
grown as monolayers in 2D and treated for three days
with the indicated concentrations of the EGFR inhibi-
tor gefitinib (A) or the ERK inhibitor SCH772984 (B)
before the cell survival was measured by the CTG
method; average +/- SEM (n ≥ 4); *, p ≤ 0.05 by
unpaired t-test.
Fig. S12. Sensitivity of D492 and D492M cells to gefi-
tinib, STLC and Fasnall with/without additional treat-
ment with 5-FU. The cells were grown in 3D Matrigel
and treated for eight days with 1 µM gefitinib (A),
5 µM (D492) or 1 µM (D492M) STLC (B) or 20 µM
(D492) or 30 µM (D492M) Fasnall (C) in combination
with 1 µM 5-FU before the cell survival was measured
by the CTG method; average +/- SEM (n = 3); **
p ≤ 0.05 by paired t-test.
Table S1. Sequencing counts for each sgRNA con-
struct for each condition.
Table S2. MAGeCK-MLE gene summary analysis
results.
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Table S3. Essential genes in the D492 and D492M
cells at indicated days post-infection. Beta scores for
each gene are provided at each time point in a cell line
if that gene was essential in that cell line at any time
point. Genes were defined as ‘essential’ if their beta
score decreased by two or more standard deviations
from the mean at an early (7 d), mid (21 d) or late
(35 d) time point.
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